Skip to main content
. Author manuscript; available in PMC: 2015 Jul 15.
Published in final edited form as: Int J Cancer. 2015 Jan 13;137(2):385–394. doi: 10.1002/ijc.29394

Figure 4.

Figure 4

sAxl and survival of HCC patients. (a) Rate of change in sAxl serum levels in patients with stable (n = 6) or progressing disease (n = 5). (b) Kaplan–Meier plot showing the overall survival of all HCC patients with high (> 18.575 ng/mL) and low sAxl serum levels (n = 122). (c) Overall survival among advanced HCC patients exhibiting high/low axl (n = 86). Numbers in brackets represent median survival in months. STA, stable disease; PRO, progressing disease; HCC, hepatocellular carcinoma.